FDA advisers review SYD-101, low-dose atropine 0.01% for pediatric myopia, on Oct 30 after a 2025 complete response letter.
|Articles|September 24, 2015
Tips for preventing the progression of myopia
David Kading, OD, FAAO, shares his tips for helping to prevent the progression of myopia in children.
Advertisement
The views expressed here belong to the author. They do not necessarily represent the views of Optometry Times or UBM Medica.
Optometry Times Editorial Advisory Board Member David Kading, OD, FAAO, shares his tips for helping to prevent the progression of myopia in children.
Looking for more information on myopia? We've got you covered!
Advertisement
Related to this article
For Maria Sampalis, OD, implementing AI isn't an excuse for practice owners to replace their staff with new technology; it should instead lift the burden of certain tasks to make for more patient visits.
Walline, American Academy of Optometry president, shares this year's conference attendance numbers, clinical pearls, and what he hopes to see in 2027.
Thomas Wong, OD, FAAO, details a session he presented alongside Ronald Gentile, MD, FACS, FASRS, at AAOpt 2026.
Christina M. Danley, OD, FOVDR, explores the many nuances that require consideration when answering a common question asked by parents of children with myopia.
Kevin Chan, OD, MS, discusses an AAOpt 2026 symposium on individualized low-dose atropine dosing for myopia and the FDA outlook ahead of the SYD-101 advisory meeting.
Raman Bhakhri, OD, FAAO, alongside Xiao Yu, OD, FAAO, discussed emerging investigational therapies for the disease during their AAOpt 2026 session.
A single Epioxa epi-on cross-linking treatment sustained a 1.9 D Kmax improvement through three years in keratoconus, with no serious adverse events reported.
Advertisement
Advertisement
Trending on Optometry Times - Clinical News & Expert Optometrist Insights
1
The screen time question: What to ask and when to look deeper
2
AAOpt 2026: Current controversies in macular hole diagnosis, management
3
AAOpt 2026: Jeffrey Walline, OD, PhD, on his conference takeaways
4
FAQ: What clinicians should know as SYD-101 heads to FDA advisory committee
5